Clinical Research Directory
Browse clinical research sites, groups, and studies.
Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment
Sponsor: Memorial Sloan Kettering Cancer Center
Summary
This study will see whether collecting and analyzing needle biopsy samples from cancer liver metastases after a tumor ablation procedure will be able to identify cancer cells that are still alive. The results of these biopsies could help determine the next treatment for your cancer, but the biopsies could cause side effects.
Official title: Clinical Trial Optimizing Tumor Ablation for Liver Metastases: Rapid Tissue Analysis Allowing for Immediate Retreatment; Metabolic Imaging Biomarker Validation; and Predictive Genetic Signatures
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2019-10-25
Completion Date
2026-10
Last Updated
2026-03-19
Healthy Volunteers
No
Conditions
Interventions
[18-F]- FDG - PET
Patients will undergo a limited non-contrast CT and first injection PET to localize the lesion
Tumor ablation (TA)
Standard ablation with the intent to create a radius of ablation at least 10 mm larger than the largest lesion diameter in order to achieve a minimum of 5 mm ablation margin around the tumor. Any radiographically-identified and biopsy-confirmed residual tumor will be treated on site with immediate ablation. This repeat ablation is not standard of care but will be performed as described for the initial ablation (in the same procedure session) and follow up will be resumed.
PET/CT Scan
Eligible patients will undergo PET/CT -guided tumor ablation as per standard IR guidelines. All patients will undergo PET/CT again, within approximately 6 weeks (+/- 2 weeks) of tumor ablation to evaluate for CN in the target tumor(s) or any sign of residual tissue enhancement, representing viable residual tumor and incomplete treatment.
Locations (1)
Memorial Sloan Kettering Cancer Center
New York, New York, United States